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Abstract
Objective—To examine the relationship between varying degrees of maternal hyperglycemia
and pregnancy outcomes.
Methods—This was a secondary analysis of a treatment trial for mild gestational diabetes
(GDM) including four cohorts: 1) 473 women with untreated mild GDM; 2) 256 women with a
positive 50-gram screen and one abnormal oral glucose tolerance test (OGTT) value; 3) 675
women with a positive screen and no abnormal OGTT values; and 4) 437 women with a normal
50-gram screen. Groups were compared by test of trend for a composite perinatal outcome
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(neonatal hypoglycemia, hyperbilirubinemia, elevated cord c-peptide level, and perinatal trauma
or death), frequency of large-for-gestational-age (LGA) infant, shoulder dystocia, and pregnancy-
related hypertension. Three-hour OGTT levels (fasting, 1, 2, and 3 hour) levels were divided into
categories and analyzed for their relationship to perinatal and maternal outcomes.
Results—There were significant trends by glycemic status among the four cohorts for the
composite and all other outcomes (p<0.001). Analysis for trend according to OGTT categories
showed an increasing relationship between fasting and all post load levels and the various
outcomes (p<0.05). Fasting glucose ≥ 90 mg/dl and 1 hour ≥ 165 mg/dl were associated with an
increased risk for the composite outcome, odds ratios and 95% CI of 2.0 (1.03-4.15) and 1.46
(1.02-2.11) to 1.52 (1.08-2.15), for the fasting and 1 hour, respectively. A 1 hour glucose ≥ 150
mg/dl was associated with an increased risk for LGA (odds ratios 1.8 (1.02-3.18) to 2.35
(1.35-4.14), however 2 and 3 hour glucose levels did not increase the risk for the composite or
LGA until well beyond current GDM diagnostic thresholds.
Conclusion—A monotonic relationship exists between increasing maternal glycemia and
perinatal morbidity. Current OGTT criteria require re-evaluation in determining thresholds for the
diagnosis and treatment of GDM.
Gestational diabetes mellitus (GDM) represents a health care burden which can be expected
to rise as the frequency of obesity increases worldwide.1 The lack of uniform criteria for
diagnosis and the reliance on observational data drawing on historic controls has limited the
accurate determination of the relationship between mild degrees of hyperglycemia and
perinatal outcomes.2 The recent HAPO study confirmed that a strong continuous
relationship exists between maternal glucose concentrations and increasing birthweight, cord
blood serum c-peptide levels and other markers of perinatal complications.3 However,
inconsistent results have been reported with respect to post glucose load levels and the risk
for outcomes such as macrosomia.4 Using patients enrolled in a blinded trial of treatment for
mild gestational diabetes, we sought to examine the relationship between varying degrees of
maternal glycemia and pregnancy outcomes.
Methods
This study is a secondary analysis of the MFMU Network randomized clinical trial for the
treatment of mild GDM.5 The study group consists of 1841 women enrolled between 24
weeks 0 days and 30 weeks 6 days of gestation. For this analysis, three groups are
considered, consisting of: (1) 473 women in the untreated arm of the randomized trial with
mild GDM defined as a fasting glucose less than 95 mg/dl with two or more post 100 gram
glucose load measurements meetings or exceeding established cut-offs6; (2) an
observational cohort of 931 women matched one to one to the randomized patients with
respect to clinical center, raceor ethnicity, and body mass index (BMI) classified as <27 kg/
m2 or ≥27kg/m2, with an elevated 50 gram screen (≥135 mg/dl) but normal oral glucose
tolerance test (OGTT) results (for some analyses, this group is further divided into those
with one abnormal value versus (n=256) those with no abnormal OGTT values n=675));
and, (3) an observational cohort of 437 women matched one to one to the untreated group
with respect to clinical center, race or ethnicity, and body mass index (BMI) classified as
<27 kg/m2 or ≥27kg/m2, with a screening value less than 120 mg/dl, and thus unlikely to
have GDM. A three-hour OGTT was not performed for this group. In order to analyze for
trend between glycemia and outcomes for patients who underwent an OGTT test, five
categories were created according to 5 mg increments for the fasting values and in 15 mg
increments for the 1, 2, and 3 hour time points of the OGTT. Fasting cut-offs were chosen
based on the HAPO study3 whereas postprandial cut-offs were based on accepted OGTT
thresholds with 15 gm increments selected to provide for adequate sample size for analysis.
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The primary study outcome consisted of a composite outcome that included perinatal
mortality, hypoglycemia, hyperbilirubinemia, elevated cord blood c-peptide level, and birth
trauma.5 Other outcomes assessed in this analysis included the frequencies of large-for-
gestational-age (LGA) (birthweight greater than the 90th centile of a U.S. reference
population) infants, shoulder dystocia, and gestational hypertension, preeclampsia, or
gestational hypertension coupled with preeclampsia.5 Trained study personnel collected
antepartum, intrapartum and post-delivery data for enrolled women and their infants at the
time of discharge from the hospital. All cases of hypertensive disorders and shoulder
dystocia underwent masked central review by two of the authors to ensure accurate
diagnosis.
For statistical analysis, baseline categorical variables were analyzed using chi square or
Fisher's exact test. Continuous variables were analyzed using the Wilcoxon rank sum test or
the Kruskal-Wallis test. The Cochrane Armitage test was used to test for trends between
OGTT category as defined above and the outcomes of interest7Multiple logistic regression
analysis was performed examining the relationship of higher OGTT glucose categories
compared to the lowest OGTT glucose category to assess whether a trend or threshold was
associated with increasing glucose levels and the outcome of interest, while adjusting for
other potential confounders. In addition to glucose categories, regression models included
maternal age, gestational age at enrollment and at delivery, parity, BMI, and race or
ethnicity. Adjusted odds ratios and profile likelihood 95% confidence intervals were
calculated.
A nominal two sided P value less than 0.05 was considered to indicate statistical
significance. This study was approved by the institutional review boards of all participating
centers.
Results
The demographics of the study population are in Table 1. Among the three groups, there was
a significant increase in maternal age with greater degrees of carbohydrate intolerance.
There were no significant differences in parity, race, and BMI among the three groups.
Figure 1 illustrates a significant increasing trend (all p<0.002) of the composite perinatal
outcome as well as the frequency of LGA infants, elevated cord c-peptide level, shoulder
dystocia, and hypertensive disorders of pregnancy among four groups (women with an
abnormal screen have been subdivided into those with or without one abnormal OGTT
value). For example, the frequency of LGA increased from 6.7% in women with a normal
screening value to 14.5% in untreated GDM. We did not observe a significant trend for
either neonatal hypoglycemia or hyperbilirubinemia considered as a separate outcome.
Figure 2 demonstrates direct comparisons between groups. An abnormal glucose screen was
associated with an increased risk for both the composite outcome and LGA infants
compared with a normal glucose screening test. Women with GDM (2 or more abnormal
values on GTT) demonstrated an increased risk for LGA, elevated c-peptide, and shoulder
dystocia compared to those with an abnormal screening test only. There were no statistically
significant differences in the frequency of any of the outcomes in women with one abnormal
value compared to those with untreated GDM.
The distribution of subjects in the five glucose categories created from the OGTT is shown
in Table 2. Significant trends for increasing frequency for LGA infants were present across
the five glucose categories of the fasting, one hour, two hour, and three hour determinations
(Figure 3). Similar trends were apparent for the composite outcome (all p<0.05), elevated
cord c-peptide level (all p<0.02) with the trends only being significant for the one and two
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hour glucose in relation to shoulder dystocia (p<0.01). A significant trend was present for all
three post glucose load times for hypertensive disorders (all p<0.03).
Logistic regression analysis controlling for maternal age, gestational age at enrollment and
at delivery, parity, BMI, and race/ethnicity for each glucose category was performed, in
which adjusted odds ratios were generated comparing higher glucose categories to the
lowest to assess whether a trend or threshold was associated with increasing glucose levels
and outcomes (Table 3). For fasting glucose, an increased risk for both elevated c-peptide
and LGA were evident at 85-89 mg/dl and for the composite at 90-94 mg/dl. For the one-
hour value, an increased risk for the composite, LGA, and hypertensive disorders was
evident at levels less than 180 mg/dl. A one-hour value of 165 to 179 mg/dl was associated
with an increased risk for the composite outcome, a one-hour values of 150 to 164 mg/dl and
165 to 179 mg/dl was associated with an increased risk for LGA, and a one-hour value of
165 to 179 was associated with an increased risk of hypertensive disorders. The highest two-
hour values were not associated with an increased risk for the composite, and the risk for
LGA was not apparent until glucose exceeded 170 mg/dl. Similarly, for the three-hour
value, an increased risk for several outcomes was present only in the highest glucose
category.
Discussion
We found a significant relationship between increasing levels of maternal glycemia and
perinatal morbidity. This graded increase in adverse maternal-fetal outcomes is observed
across the spectrum of carbohydrate intolerance and includes glucose values below current
cut-offs for the diagnosis of gestational diabetes.2,3,8 This observation provides additional
information as experts continue to debate what constitutes appropriate thresholds for the
diagnosis of GDM.
Previous studies have documented that an abnormal glucose screening test alone is an
independent predictor of macrosomia. 9,10 In addition to an increased risk for LGA infants,
we have also documented a risk exists for other neonatal morbidities as well as shoulder
dystocia in this group of women. Because of a perceived intermediate risk for fetal
macrosomia, some have advocated follow-up diagnostic testing or close surveillance for
fetal overgrowth during the third trimester for women with an abnormal screening test (and
normal OGTT) discovered between 24-28 weeks of gestation.11 Recently, a small
randomized trial has shown a reduction in large infants in women with abnormal screening
results receiving nutritional intervention compared with controls.12
Although our sample size is relatively small, our findings support the hypothesis of an
increased risk of perinatal outcomes with one abnormal OGTT value compared to the
normal OGTT group, both in the trend analysis and in the comparison with the untreated
mild GDM (at least two abnormal OGTT values) group. The finding of similar frequencies
of various perinatal outcomes among women with one abnormal OGTT value compared
with untreated mild GDM is important as some previous studies have compared this group
with treated GDM subjects and thus have been unable to estimate their true level of risk.13
Originally, O'Sullivan and Mahan required two values to be abnormal on the diagnostic
OGTT in order to minimize misclassification due to rapid glucose absorption or laboratory
error.14 An analysis from the HAPO study demonstrating independent risks at each timed
OGTT value has suggested that the criteria for the diagnosis of GDM should be based on the
presence of one abnormal OGTT value. In an effort to define GDM, Sacks and colleagues
were among the first to attempt to quantitate the relationship between maternal glucose
levels and birthweight centiles.8 However, within the ranges of glucose studied in over three
thousand women, these authors could not establish a “clinically meaningful” threshold for
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diagnosis. The HAPO study also failed to yield any apparent inflection points when
comparing maternal glycemia to both perinatal and maternal outcomes. Thus, any proposed
thresholds for diagnosis, as Sacks predicted, will rely on expert opinion and be based on a
consideration of relative risk.8 Our analysis revealed that the risk for LGA and other
morbidities to be present at fasting and one hour levels below the current criteria for the
diagnosis of GDM. However, risks for LGA did not become significant until two and three
hour values exceeded the Carpenter-Coustan thresholds.6 After controlling for confounders,
Sermer and colleagues reported that only fasting glucose could be related to macrosomia
(birthweight >4000g), whereas others have suggested that the one-hour postprandial level,
representing the peak of the glucose response curve is most significant.2
We do note several limitations of this secondary analysis. First, we were able to only
consider OGTT data from a cohort of women who failed the 50 gram glucose screen. These
individuals likely have an intermediate level of carbohydrate intolerance and also appear to
have an increased risk for adverse perinatal outcomes compared to women with normal
screening. We chose to generate odds ratios for outcomes in comparison to the lowest
glucose categories for this reason. Thus, our finding of increased two and three hour OGTT
thresholds for several outcomes among such women may actually be considered even more
significant. Our study also utilized the three hour, 100 gram OGTT, which, while standard
for use in pregnancy in the United States, is not the diagnostic test common in many areas of
the world. This limits direct comparisons to 75 gram, two-hour OGTT data found in other
reports.8 While we analyzed outcomes in relation to greater than one thousand OGTTs, our
treatment trial did not include a sample size sufficient to suggest precise cut-offs for the
diagnosis of GDM. Current proposed recommendations for new diagnostic criteria for
GDM, if adopted, will substantially increase the frequency of this diagnosis.15 While two
RCTs now demonstrate a treatment benefit to women meeting specific OGTT criteria,
evidence is lacking concerning treating women with thresholds outside those we studied as
well as one abnormal 75 gram OGTT value.5,16 The results of treatment trials as well as the
current analysis, will hopefully further aid professional organizations as they consider the
most cost effective approach to the diagnosis and treatment of GDM.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development
(HD27915, HD34116, HD40485, HD34208, HD27869, HD40500, HD40560, HD34136, HD40544, HD27860,
HD40545, HD53097, HD21410, HD27917, HD40512, HD53118, HD36801), General Clinical Research Centers
Grant (M01-RR00034) and the National Center for Research Resources (UL1-RR024989, M01-RR00080, UL1-
RR025764, C06-RR11234 ) and does not necessarily represent the official views of the NICHD or the National
Institutes of Health.
References
1. Chen Y, Quick WW, Yang W, Zhang Y, Baldwin A, et al. Cost of gestational diabetes in the United
States in 2007. Population Health Management. 2009; 12:165–174. [PubMed: 19534581]
2. Sermer M, Naylor D, Phil D, Gare DJ, et al. for the Toronto Tri-Hospital Gestational Diabetes
Investigators. Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637
women without gestational diabetes. Am J Obstet Gynecol. 1995; 173:146–56. [PubMed: 7631672]
3. The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes.
N Engl J Med. 2008; 358:1991–2002. [PubMed: 18463375]
Landon et al. Page 5













4. Dodd JM, Crowther CA, Antoniou G, Baghurst P, Robinson JS. Screening for gestational diabetes:
The effect of varying blood glucose definitions in the prediction of adverse maternal and infant
health outcomes. Aust NZ J Obstet Gynaecol. 2007; 47:307–12.
5. Landon MB, Spong CY, Thom E, Carpenter MW, et al. A multicenter randomized trial of treatment
for mild gestational diabetes. N Engl J Med. 2009; 361:1339–48. [PubMed: 19797280]
6. Carpenter DR, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet
Gynecol. 1982; 144:768–73. [PubMed: 7148898]
7. Agresti, Alan. Categorical Data Analysis. 1st. New York: Wiley; 1990. p. 100-102.
8. Sacks DA, Greenspoon JS, Abu-Fadil S, Henry HM, et al. Toward universal criteria for gestational
diabetes: The 75-hour glucose tolerance test in pregnancy. Am J Obstet Gynecol. 1995; 172:607–
14. [PubMed: 7856693]
9. Leiken LE, Jenkins JH, Pomerantz GA, Klein I. Abnormal glucose screening tests in pregnancy: a
risk factor for fetal macrosomia. Obstet Gynecol. 1987; 69:570–73. [PubMed: 3822298]
10. Stamilio DM, Olsen T, Ratcliffe S, Sehdey HM, Macones GA. False-positive 1-h glucose
challenge test and adverse perinatal outcome. Obstet Gynecol. 2004; 103:148–56. [PubMed:
14704259]
11. Neiger R, Coustan DR. The role of repeat glucose tolerance tests in the diagnosis of gestational
diabetes. Am J Obstet Gynecol. 1991; 165:787–90. [PubMed: 1951534]
12. Bonomo M, Corsica D, Conclaves D, Motet G, et al. Evaluating the therapeutic approach in
pregnancies complicated by borderline glucose intolerance: a randomized clinical trial. Diabet
Med. 2005; 22:1536–41. [PubMed: 16241919]
13. Langer O, Brustman L, Anyaegbunam A, Mazze R. The significance of one abnormal glucose
tolerance test value on adverse outcome in pregnancy. Am J Obstet Gynecol. 1987; 157:758–63.
[PubMed: 3631178]
14. O'Sullivan JB, Maban CM, Charles D, Dandrow RV. Screening criteria for high-risk gestational
diabetic patients. Am J Obstet Gynecol. 1973; 116:895–900. [PubMed: 4718216]
15. IADPSG Consensus Panel. International Association of Diabetes and Pregnancy Study Groups
(IADPSG) recommendations on the diagnosis and classification of hypertension in pregnancy.
Diabetes Care. 2010; 33:676–682. [PubMed: 20190296]
16. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of
gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005; 352:2477–86.
[PubMed: 15951574]
Landon et al. Page 6














Frequencies of various outcomes according to glucose groupings. A = 50 gm screen <120
mg/dl, B = 50 gm screen ≥135mg/dl with normal OGTT, C = 50 gm screen ≥135 mg/dl with
one abnormal OGTT value, D = GDM (two abnormal OGTT values).
Number of Subjects: Composite: A: 407 B: 626 C: 238 D: 440
LGA: A: 421 B: 652 C: 251 D: 454
C-Peptide: A: 365 B: 549 C: 211 D: 403
Shoulder Dystocia: A: 423 B: 653 C: 252 D: 455
Gestational Hypertertension: A: 423 B: 653 C: 252 D: 455
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Comparisons of outcomes between glucose groups.
Abnormal versus Normal 50 Gram Screen: Composite: 279/864 (Abnormal Screen),
105/407 (Normal Screen)
LGA: 95/903 (Abnormal Screen), 28/421 (Normal Screen)
C-Peptide (C-Pep): 119/760 (Abnormal Screen), 45/365 (Normal Screen)
Shoulder Dystocia (ShD): 17/905 (Abnormal Screen), 3/423 (Normal Screen)
Gestational Hypertension/Preeclampsia (Gest.HTN/Preec): 83/905 (Abnormal Screen),
31/423 (Normal Screen)
Abnormal Screen versus GDM: Composite: 279/864 (Abnormal Screen), 163/440 (GDM)
LGA: 95/903 (Abnormal Screen), 66/454 (GDM)
C-Peptide (C-Pep): 119/760 (Abnormal Screen), 92/403 (GDM)
Shoulder Dystocia (ShD): 17/905 (Abnormal Screen), 18/455 (GDM)
Gestational Hypertension/Preeclampsia (Gest.HTN/Preec): 83/905 (Abnormal Screen),
62/455 (GDM)
GDM versus 1 Abnormal OGTT Value: Composite: 163/440 (GDM), 75/238 (1 Abnormal
OGTT)
LGA: 66/454 (GDM), 28/251 (1 Abnormal OGTT)
C-Peptide (C-Pep): 92/403 (GDM), 40/211 (1 Abnormal OGTT)
Shoulder Dystocia (ShD): 18/455 (GDM), 6/252 (1 Abnormal OGTT)
Gestational Hypertension/Preeclampsia (Gest.HTN/Preec): 62/455 (GDM), 29/252 (1
Abnormal OGTT)
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Figure 3. Percentage of infants with LGA by OGTT Glucose Level
Fasting OGTT (mg/dL): (1) < 75, (2) 75-79, (3) 80-84, (4) 85-89, (5) 90-94
1 Hour OGTT (mg/dL): (1) < 150, (2) 150-164, (3) 165-179, (4) 180-194, (5) ≥ 195
2 Hour OGTT (mg/dL): (1) <125, (2) 125-139, (3) 140-154, (4) 155-169, (5) ≥ 170
3 Hour OGTT (mg/dL): (1) < 110 (2) 110-124, (3) 125-139, (4) 140-154, (5) ≥ 155.
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Table 1
Demographic Information
50 gm Less Than 120 mg% (no
OGTT)
50 gm 135 mg% or higher (normal
OGTT)
Untreated GDM p-value
N 437 931 473
Age (yr) 25.1 ± 5.3 27.4 ± 5.5 28.9 ± 5.6 < 0.0001
Nulliparous (%) 37.3 31.9 35.3 0.12
Race (%) 0.70
 African American 12.8 12.4 11.4
 Hispanic 58.6 58.3 56
Caucasian/other 28.6 29.3 32.6
BMI at entry (kg/m2) 29.9 ± 5.8 30.1 ±5.3 30.2 ± 5.1 0.23
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